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EMPIRICAL RESEARCH FOR WILLINGNESSTO PAYFOR ONE
QALY GAIN
Ohkusa Y, Sugawara T
National Institute of Infectious Diseases, Shinjuku,Tokyo, Japan
OBJECTIVE: The monetary evaluation for QALY gain is neces-
sary and important information for decision making about
medical or public health policies. Even though there is one empir-
ical research about it, it used direct methods to estimate its WTP
and thus it has a lot of problems. This paper aims to study the
same purpose but by using Conjoint analysis. METHODS: A
survey was conducted in the 2005 ﬁscal year and questionnaires
were distributed and collected from 773 households, of which
the return rate was 88%. The subjects are 1297 adults over age
20. In addition to socio-economic characteristics, in this survey
respondents were asked a hypothetical question for Conjoint
analysis; whether they would agree to the medical care under the
hypothetical situation in regards to cost, duration, the number
of patients, and health status. We also performed sensitive analy-
sis in regards to explanatory variables in the estimation equa-
tion, discount factors, and QOL evaluation for health status.
RESULTS: In all equation, the estimated coefﬁcients of total cost
are signiﬁcantly negative and those of QALY gain are signiﬁ-
cantly positive. CONCLUSIONS: WTP per QALY gain is esti-
mated to be 635 to 675 thousand Japanese yen or 5773 to 6136
US$ assuming 1US$ = 110 Japanese yen. Income does not affect
WTP per QALY signiﬁcantly.
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MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS:
ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES
Foster JM1,Van der Molen T1, Caeser M2, Hannaford P3
1University of Groningen, Groningen,The Netherlands, 2ALTANA
Pharma AG, Konstanz, Germany, 3University of Aberdeen, Aberdeen,
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INTRODUCTION: Side effects include drug-induced symptoms
which are predominantly communicated by patient self-report.
This year, the FDA produced draft recommendations for the val-
idation of patient-reported outcomes, for use in medical product
development studies. The growing interest in side effects in
medical research and the regulatory environment, presents an
urgent need for properly developed patient-reported outcome
measures of drug side effects. These measures must be valid, reli-
able and reproducible. METHODS: To assess the psychometric
properties of patient-reported side effect symptom scales, and to
describe and evaluate the methodologies used to create them.
RESULTS: Fifteen existing scales were identiﬁed and reviewed.
There was wide variation in the extent to which the psychome-
tric properties of the instruments had been reported or tested.
There were disagreements amongst scale developers concerning
the appropriateness of use of certain reliability tests which are
usually routinely undertaken during questionnaire development.
The responsiveness testing of side effect scales may be problem-
atic to carry out and testing was limited amongst reviewed scales.
Since any symptom of a drug intervention may be associated
with everyday health problems, the disease being treated, the
drug treatment or a combination of these causes, measuring
drug-related side effects is complicated. This complexity impacts
upon all aspects of the psychometric testing of patient–reported
scales, creating unique challenges for their developers, who must
create tools which appropriately discriminate between side
effects and symptoms. CONCLUSION: The potential usefulness
of patient-reported side effect scales is broad: from research
outcome to clinical monitoring. However, a consensus must be
reached on suitable methods for the development of such scales.
The complexity of side effect measurement may necessitate the
introduction of new approaches for the assessment of the relia-
bility and responsiveness of these scales.
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HOSPITAL PHARMACY DRUG DELIVERY TIME: A WORK FLOW
MANAGEMENT ISSUE
Pierce CA1, Baker JJ2, McClard C2
1The Resource Group, Richﬁeld, OH, USA, 2The Resource Group,
Pickton,TX, USA
OBJECTIVE: Drug delivery delays are a recurring management
issue that causes costly disruptions in hospital work ﬂow. This
project examines reported delivery time from the hospital phar-
macy to the hospital outpatient department where the drug or
biologic is to be administered. The focus is upon drugs that are
expensive, that require reconstitution and that are often prepared
only after notiﬁcation that the patient has arrived. METHODS:
Data were collected from 54 hospital pharmacies, including on-
site observations of pharmacy activities and related infusion
therapy in hospital outpatient departments (HOPDs) in 19 states
(n = 24) and from a telephone survey of other hospital DOPs
located in 17 states (n = 30). Survey instruments were pretested.
The sampling frame was a broad-based convenience sample.
Facility-speciﬁc data were entered into a database and matched
with facility demographics retrieved from a government data-
base. Unit of analysis was the pharmacy. Statistical analysis
yielded descriptive statistics. RESULTS: The on-site observers
determined that those HOPDs that delivered the drug to be
infused from the main pharmacy (54.2%) incurred a statistically
signiﬁcant mean wait time of 37.5 minutes. The remaining facil-
ities (45.8%) incurred negligible wait times because the drug was
reconstituted adjacent to or on site. Respondents to the tele-
phone survey reported a 17.4 minute mean delivery time regard-
less of pharmacy location. Tasks contributing to wait time
included mixing, dispensing and transporting. Delivery was
made by pharmacy technicians in 80.8% of facilities and by spe-
cially designated transport staff provided by the pharmacy
department in 19.2% of the facilities surveyed. CONCLU-
SIONS: Hospital pharmacy decision-makers need actionable
information in order to better manage drug delivery delays that
disrupt work ﬂow and decrease patient satisfaction. This study
provides detailed activity analysis information and process
mapping that can be readily applied to facility-speciﬁc relevant
pharmacy stafﬁng and management decisions.
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PROPOSED CHANGES TO PHYSICIAN FEE SCHEDULE: 2007
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Pierce CA1, Baker JJ2
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OBJECTIVE: The Centers for Medicare and Medicaid Services
(CMS) has proposed methodological changes to the computation
of 2007 physician fee schedule practice expense. The proposed
changes appear to reduce payment for drug administration. This
study explores the methodological design of these proposed
changes and seeks to identify primary drivers within the method-
ology. METHODS: Various methods of computing practice
expense for 2007 as proposed by CMS were collected and cate-
gorized in a methods database format. Data sources and formu-
las for each proposed method were identiﬁed. Current
computation methods in effect for calendar year 2006 were then
identiﬁed and divided into segments for purposes of comparison.
Proposed methods were compared against each other and against
the payment structure currently in effect. This comparative
